Non-small cell lung cancer

Recent Findings on Non-small cell lung cancer

• A pooled analysis of the KCSG-LU20-15 and LU21-01 phase II trials evaluated the central nervous system activity of lazertinib in patients with EGFR-mutated NSCLC, CNS involvement, and prior EGFR tyrosine-kinase inhibitor exposure. The study assessed treatment efficacy in a setting that includes intracranial disease and is relevant to measures such as intracranial objective response rate, disease control, and progression-free survival 42670582Aug.

• A clinical validation and implementation study examined mSTOP, a longitudinal machine-learning model based on serum tumor markers. The model had previously been developed to identify patients with NSCLC who do not benefit from immune checkpoint inhibitor treatment; the reported work focused on its clinical implementation and early identification of nonresponders. This research connects molecular and laboratory monitoring with treatment selection for immunotherapies such as atezolizumab and nivolumab 42054314Apr.

• A drug-delivery study investigated a multifunctional nano-chitosan conjugate for treatment of NRAS-mutant-harbouring lung carcinoma. The investigators modified the mitochondria-targeting YKWYYRGAA peptide through N-methylation and N-dimethylation and combined it with the nano-chitosan carrier. The approach was designed to integrate mitochondrial targeting and drug delivery in NSCLC treatment, extending research themes involving cytotoxicity and mitochondria-associated cell-death mechanisms 42230031Jun.

• Another study explored p40-engineered chimeric antigen receptor T cells directed against CD276 in NSCLC. The engineered construct, designated p40-H3BBz, was evaluated for its therapeutic potential and anti-tumor activity against NSCLC. The work represents an experimental cellular-immunotherapy approach distinct from conventional chemotherapy and immune checkpoint blockade 42262195Jun.

• An investigation of Inonotus obliquus polysaccharides used integrated untargeted metabolomics of mouse serum and quantitative proteomics of xenograft tumors to examine potential anti-NSCLC mechanisms. The analysis identified candidate biological pathways associated with the treatment, although the reported pathways were described as requiring further experimental validation. The study extends the literature’s cytotoxicity, apoptosis, and metabolic-mechanism themes through combined systemic and tumor-level molecular profiling 42532236Jul.

• A precision-oncology study assessed whether lung-cancer histology and molecular profiles could be predicted from small bronchoscopic tumor specimens. Somatic mutations were identified by massively parallel sequencing, while proteomics-based NSCLC subtypes were characterized using mass spectrometry. This work extends molecular profiling of lung cancer by integrating histologic prediction with genomic and proteomic information from limited clinical samples 42509268Jul.

• A real-world outcomes study evaluated whether pseudonymized electronic medical records collected under Japan’s Next-Generation Medical Infrastructure Act could reconstruct a patient cohort comparable to the Japanese subgroup of the OAK trial. The cohort consisted of patients with NSCLC treated with atezolizumab, and the investigators evaluated whether progression-free survival and overall survival could be reconstructed from the unstructured clinical data 42489799Jul.

• A BMJ Case Reports publication described long-term survival in a man in his 50s with neurofibromatosis type 1-associated diffuse lung disease complicated by NSCLC with mediastinal invasion. The case places NSCLC in the context of an uncommon underlying diffuse lung disorder and highlights the clinical heterogeneity of lung cancer presentations 42481140Jul.